NCT02753504View on ClinicalTrials.gov

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Dyslipidemia
Interventions
DRUG

CKD-519

DRUG

placebo

Trial Locations (1)

120-752

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY